Recent financial developments include Concentra Biosciences acquiring struggling biotech IGM Biosciences as part of an ongoing buyout streak and Innovent Biologics raising HKD 4.3 billion ($547 million) to advance R&D and global growth. Tempus AI increased its convertible senior note offering to $650 million to manage debt and fund corporate activities. These transactions exemplify active capital movements and consolidation trends amid fluctuating market conditions in biotechnology.